Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

Hair cloning claims by Dr. Gho are widely considered a scam, with skepticism about the effectiveness of his hair stem cell transplantation. Users suggest that if it were effective, wealthy individuals would opt for it over traditional methods like FUE transplants.

Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

Stem cell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stem cells could potentially offer a more permanent solution.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

User questions credibility of a hair loss "cure" found by a non-expert and warns against wasting money on unproven supplements. Others discuss trying natural extracts and the importance of researching the enzyme 3ADH for potential hair growth benefits.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.

Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.

CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.